30-Day Non-Relapse Mortality In Multiple Myeloma Patients Treated with Bispecific T-cell Engagers: A Fear Analysis

Key Points

• Non-relapse mortality rates were evaluated within 30 days post-treatment initiation.
• The study found a significant rate of 5% non-relapse mortality among the 200 assessed patients after treatment.
• Assessment based on clinical outcomes focused on non-relapse mortality due to T-cell therapy with bispecific agents.
• These findings indicate a need for careful monitoring of non-relapse complications in bispecific T-cell engager treatments.